RA
SRPT icon

Rosalind Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Rosalind Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-57,400
Closed -$5.54M – 39
2023
Q4 		$5.54M Buy
+57,400
New +$5.51M 4.56% 11

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Rosalind Advisors's SRPT Position: Q1 2024 in Review

Rosalind Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 57,400 shares — an estimated $5.54M sold.

Rosalind Advisors first reported a position in SRPT in Q4 2023 and held it in 1 quarter. The position peaked at $5.54M in Q4 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Rosalind Advisors reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Rosalind Advisors sold 57,400 Sarepta Therapeutics shares in Q1 2024, an estimated $5.54M.
  • Rosalind Advisors first reported a position in Sarepta Therapeutics in Q4 2023 and held it in 1 quarter.
  • Rosalind Advisors's Sarepta Therapeutics position peaked at $5.54M in Q4 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.